Did your child recently start showing Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS/PANDAS) symptoms? Consider enrolling them in the ProPANS IVIG study.
This study will look at how well an IVIG study drug* may work for children 6 years-17 years of age who have PANS/PANDAS. Other study requirements apply.
*This drug has been FDA approved to address other conditions, but is not FDA approved for the use of addressing PANS symptoms in children.
The ProPANS study will be conducted at a select number of medical universities and institutions. For more information or to learn if your child may qualify, please contact:
Study participants receive at no cost:
Access to a new IVIG study drug that may help with managing PANS/PANDAS
All participants will receive the study drug and placebo (no active ingredients). Participants will be randomly assigned to receive the study drug in either the first or second half of the study
Study support and study-related monitoring by a healthcare team
Help with study-related travel expenses, including reimbursements for lodging, transportation, and meals
Education about PANS/PANDAS
The opportunity to help advance PANS/PANDAS research
Paticipating Clinical Trial Sites -
Not sure about the trial?
If you are looking for medical care, but don't qualify for the trial. PACE partners with top universities and institutions where children affected with PANS will be appropriately treated, and where the country’s top researchers and physicians can collaborate on best practices, research, and treatment options.